Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Safety and immunogenicity of ETHIORAB rabies vaccine
Journal of Vaccines and Vaccination, Volume 4, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
Worldwide rabies in dogs is the source of 99% of human infections. This makes dogs potential reservoir and transmitters to human being. Pre and post-exposure prophylaxis are means of protection against the rabies virus. The main objective of this experiment was to determine the safety and immunogenicity of Vero cell culture based rabies vaccine "ETHIORAB" manufactured by Ethiopian Health and Nutrition Research Institute, Vaccine and Diagnostic Production Directorate. The obtained vaccine was tested on mice and satisfactory safety results were observed. Random Clinical Trial (RCT) design was used for this experiment. Twelve experimental dogs from local breed were duly conditioned during a quarantine period and assigned to two groups randomly. Group I (cases) were vaccinated subcutaneously with 1 ml of ETHIORAB. Dogs in group II served as non-vaccinated controls. To evaluate the titer of the rabies virus neutralizing antibodies (VNA), sera were analyzed by Fluorescent Antibody Virus Neutralization (FAVN) test. Serum neutralizing antibody geomtric mean titers (GMT) to rabies virus was determined at days 7, 15, 21, 30, 60 and 90. Geomtric mean titers were equal to 1.55, 1.73, 2.02, 3.45, 3.57 and 3.17 IU/ml respectively. All dogs showed VNA titers higher than the 0.5 IU/ml mandated WHO recommended threshold. This study indicated ETHIORAB rabies vaccine manufactured in Ethiopia is safe and immunogenic. © 2013 Hurisa B, et al.
Authors & Co-Authors
Hurisa, Birhanu
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Tegbaru, Belete
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Nölkes, Dagmar
Ethiopia, Dire Dawa
Haramaya University
Mengesha, Abebe
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Kebede, Gezahegn
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Kerga, Sisay
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Adhanom, Amdemicael
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Godana, Alemayehu
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Nigussie, Dereje
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Newayesilasie, Bethelehem
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Gebrewold, Gashaw
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Bankovskiy, Denis
Russian Federation
Pokrov Plant of Biologics
Metlin, Artem
Russian Federation, Vladimir
Federal State-financed Institution Federal Centre for Animal Health
Urga, Kelbessa
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Statistics
Citations: 14
Authors: 14
Affiliations: 4
Identifiers
Doi:
10.4172/2157-7560.1000195
Research Areas
Food Security
Study Design
Randomised Control Trial
Study Approach
Quantitative
Study Locations
Ethiopia